Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Indivior to cancel secondary listing in London

(Sharecast News) - Drugmaker Indivior has announced plans to cancel its secondary listing in London, just a year after moving its primary listing to the Nasdaq. The company, which in May 2024 said it would stay listed in London "for as long as it is considered to be in the best interests of Indivior and its shareholders as a whole", said the decision to cancel its listing better reflects its geographic presence, with more than 80% of net revenues generated from the US. Over 70% of holders of its ordinary shares are also located in the US,.

The cancellation would also eliminate the "cost and complexity" of maintaining a secondary listing, while the timing of material news announcements can now align with industry peers in the US.

Lastly, Indivior said the the liquidty on Nasdaq "far outweighs liquidity on the LSE", with trading on the US index accounting for 75% of total trading volumes across both exchanges over the past 30 days.

As such, the company has requested to the Financial Conduct Authority to cancel its secondary listing.

"We are pleased to announce this key milestone for Indivior following our evaluation period," said chair David Wheadon.

"A single primary listing on Nasdaq best reflects the profile of Indivior's business. We appreciate the support received from shareholders for this initiative and look forward to capitalizing on the expected benefits of this move, including reductions in cost and complexity."

Indivior's share price was down 0.4% at 940.5p by 0836 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.